Abstract:Alzheimer's disease (AD) is the leading cause of dementia, afflicting 5 million Americans and costing over 200 billion dollars per year. The mechanisms involved in AD pathogenesis are still poorly understood. Moreover, no therapy is available to cure AD or to slow down its progression. The study of new pathways involved in AD pathogenesis is necessary to develop new therapeutic targets. The 12/15-lipoxygenase enzymatic pathway (12/15-LO) is upregulated in postmortem brain tissues and cerebrospinal fluid of AD patients. Its genetic absence or pharmacological inhibition prevents the development of the AD-like phenotype in transgenic mouse models of the disease. However, whether targeting pharmacologically this pathway after the neuropathological lesions and behavioral impairments are well established could be a viable therapeutic strategy against AD remain to be investigated. To this end, 12-month-old triple transgenic mice (3xTg) and their appropriate wild type controls were randomized to receive a specific and selective pharmacological inhibitor of 12/15-LO, PD146176, or placebo. After 3 months, when the animals were 15-month-old, treated and untreated groups were assessed for the effects of the drug on their behavioral impairments and neuropathology. While 15-month-old 3xTg mice on placebo by the end of the study showed a worsening of their memory and learning abilities, as assessed by the fear conditioning paradigms, mice at the same age receiving the PD146176 performed better than baseline in the same test. Compared with placebo, treated mice had significantly less Abeta levels and deposition, improved tau pathology as well as markers of synaptic integrity. Additionally, the same PD146176 treated animals showed a significant upregulation of autophagy markers, suggesting an involvement of this pathway in the pharmacological effect. In vitro experiments demonstrated that 12/15-LO effect on tau metabolism is mediated by modulating neuronal autophagy system. These studies provide new insights into the disease-modifying action of pharmacological inhibiting 12/15-LO as a viable therapeutic approach for AD treatment. They represent the successful completion of the preclinical studies for the development of this class of drug as clinically applicable therapy for the disease.

The Antiproteinopathy, Antioxidant, and Antiapoptotic Effects of Methylene Blue and 4-Phenylbutyric Acid Alone, and in Combination on Familial Alzheimer's Disease PSEN1 I416T Cholinergic-Like Neurons

Combination of Tramiprosate, Curcumin, and SP600125 Reduces the Neuropathological Phenotype in Familial Alzheimer Disease PSEN1 I416T Cholinergic-like Neurons

Minocycline mitigates Aβ and TAU pathology, neuronal dysfunction, and death in the PSEN1 E280A cholinergic-like neurons model of familial Alzheimer's disease

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

A New Chiral Pyrrolyl α-Nitronyl Nitroxide Radical Attenuates β-Amyloid Deposition and Rescues Memory Deficits in a Mouse Model of Alzheimer Disease

Cholinergic-like neurons and cerebral spheroids bearing the PSEN1 p.Ile416Thr variant mirror Alzheimer's disease neuropathology

Dual Effect of Prussian Blue Nanoparticles on Aβ40 Aggregation: β-Sheet Fibril Reduction and Copper Dyshomeostasis Regulation

Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease

Blood-brain barrier Permeable nanoparticles for Alzheimer's disease treatment by selective mitophagy of microglia

Methylene Blue Attenuates Impaired Cognitive Functions and Reduces Hippocampal Aβ Levels and Oxidative Stress in D-Galactose-Induced Alzheimer's Disease Mouse Model

Treatment with 1, 10 Phenanthroline-5-Amine Reduced Amyloid Burden in a Mouse Model of Alzheimer's Disease

Pathological BBB Crossing Melanin-Like Nanoparticles as Metal-Ion Chelators and Neuroinflammation Regulators against Alzheimer’s Disease

A Multifunctional (-)-Meptazinol-Serotonin Hybrid Ameliorates Oxidative Stress-Associated Apoptotic Neuronal Death and Memory Deficits via Activating the Nrf2/Antioxidant Enzyme Pathway

Extending Lifespan of Alzheimer’s Mode Nematode CL4176 Using a Novel Bifunctional Peptide with Inhibition of Β -Amyloid Aggregation and Anti-oxidation

Pathological BBB Crossing Melanin-Like Nanoparticles As Metal-Ion Chelators and Neuroinflammation Regulators Against Alzheimer's Disease.

Biofilm-camouflaged Prussian blue synergistic mitochondrial mass enhancement for Alzheimer's disease based on Cu2+ chelation and photothermal therapy

4-Phenylbutyric Acid (4-PBA) Derivatives Prevent SOD1 Amyloid Aggregation In Vitro with No Effect on Disease Progression in SOD1-ALS Mice

Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons

12/15-LIPOXYGENASE INHIBITION REVERSES COGNITIVE IMPAIRMENT, AMYLOIDOSIS, TAU AND SYNAPTIC PATHOLOGY BY STIMULATING AUTOPHAGY IN THE BRAIN OF AGED 3XTG MICE

Lipid-polymer hybrid nanoparticles loaded with N-acetylcysteine for the modulation of neuroinflammatory biomarkers in Human iPSC-Derived PSEN2 (N141I) Astrocytes as a model of Alzheimer's Disease

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy